These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 11485406)

  • 41. A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose.
    Tsuda Y; Parkins CJ; Caposio P; Feldmann F; Botto S; Ball S; Messaoudi I; Cicin-Sain L; Feldmann H; Jarvis MA
    Vaccine; 2015 May; 33(19):2261-2266. PubMed ID: 25820063
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Immunobiological properties of vp24 protein of Ebola virus expressed by recombinant vaccinia virus].
    Chepurnov AA; Ternovoĭ VA; Dadaeva AA; Dmitriev IP; Sizikova LP; Volchkov VE; Kudoiarova NM; Rudzevich TN; Netesov SV
    Vopr Virusol; 1997; 42(3):115-20. PubMed ID: 9297340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of the cell-mediated immunity induced by alphavirus replicon-vectored DNA vaccines against classical swine fever in a mouse model.
    Zhao HP; Sun JF; Li N; Sun Y; Xia ZH; Wang Y; Cheng D; Qi QF; Jin ML; Qiu HJ
    Vet Immunol Immunopathol; 2009 May; 129(1-2):57-65. PubMed ID: 19150136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus.
    Saha S; Yoshida S; Ohba K; Matsui K; Matsuda T; Takeshita F; Umeda K; Tamura Y; Okuda K; Klinman D; Xin KQ; Okuda K
    Virology; 2006 Oct; 354(1):48-57. PubMed ID: 16945400
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge.
    Domi A; Feldmann F; Basu R; McCurley N; Shifflett K; Emanuel J; Hellerstein MS; Guirakhoo F; Orlandi C; Flinko R; Lewis GK; Hanley PW; Feldmann H; Robinson HL; Marzi A
    Sci Rep; 2018 Jan; 8(1):864. PubMed ID: 29339750
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.
    Pushko P; Bray M; Ludwig GV; Parker M; Schmaljohn A; Sanchez A; Jahrling PB; Smith JF
    Vaccine; 2000 Aug; 19(1):142-53. PubMed ID: 10924796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein.
    Kumar D; Gauthami S; Uma M; Nagalekshmi K; Rao PP; Basu A; Ella KM; Hegde NR
    Viral Immunol; 2018 Sep; 31(7):500-512. PubMed ID: 30095362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.
    Warfield KL; Swenson DL; Olinger GG; Nichols DK; Pratt WD; Blouch R; Stein DA; Aman MJ; Iversen PL; Bavari S
    PLoS Pathog; 2006 Jan; 2(1):e1. PubMed ID: 16415982
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.
    Lee JS; Groebner JL; Hadjipanayis AG; Negley DL; Schmaljohn AL; Welkos SL; Smith LA; Smith JF
    Vaccine; 2006 Nov; 24(47-48):6886-92. PubMed ID: 16828936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sequence analysis of the GP, NP, VP40 and VP24 genes of Ebola virus isolated from deceased, surviving and asymptomatically infected individuals during the 1996 outbreak in Gabon: comparative studies and phylogenetic characterization.
    Leroy EM; Baize S; Mavoungou E; Apetrei C
    J Gen Virol; 2002 Jan; 83(Pt 1):67-73. PubMed ID: 11752702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens.
    Shahhosseini S; Das D; Qiu X; Feldmann H; Jones SM; Suresh MR
    J Virol Methods; 2007 Jul; 143(1):29-37. PubMed ID: 17368819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections.
    Geisbert TW; Hensley LE; Geisbert JB; Jahrling PB
    Virology; 2002 Feb; 293(1):15-9. PubMed ID: 11853394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complete genome sequence of an Ebola virus (Sudan species) responsible for a 2000 outbreak of human disease in Uganda.
    Sanchez A; Rollin PE
    Virus Res; 2005 Oct; 113(1):16-25. PubMed ID: 16139097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses.
    Marzi A; Feldmann F; Geisbert TW; Feldmann H; Safronetz D
    Emerg Infect Dis; 2015 Feb; 21(2):305-7. PubMed ID: 25625358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies.
    Ye L; Lin J; Sun Y; Bennouna S; Lo M; Wu Q; Bu Z; Pulendran B; Compans RW; Yang C
    Virology; 2006 Aug; 351(2):260-70. PubMed ID: 16678231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Towards a vaccine against Ebola virus.
    Geisbert TW; Jahrling PB
    Expert Rev Vaccines; 2003 Dec; 2(6):777-89. PubMed ID: 14711361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of Filovirus Interferon Antagonists on Responses of Human Monocyte-Derived Dendritic Cells to RNA Virus Infection.
    Yen BC; Basler CF
    J Virol; 2016 May; 90(10):5108-5118. PubMed ID: 26962215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.
    Li W; Ye L; Carrion R; Mohan GS; Nunneley J; Staples H; Ticer A; Patterson JL; Compans RW; Yang C
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S398-403. PubMed ID: 25877553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.